"10.1371_journal.pone.0062540","plos one","2013-04-29T00:00:00Z","Carlos López-Gómez; Almudena Pino-Ángeles; Teresa Órpez-Zafra; María Jesús Pinto-Medel; Begoña Oliver-Martos; Jesús Ortega-Pinazo; Carlos Arnáiz; Cristina Guijarro-Castro; Jezabel Varadé; Roberto Álvarez-Lafuente; Elena Urcelay; Francisca Sánchez-Jiménez; Óscar Fernández; Laura Leyva","Research Laboratory. Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya, Málaga, Spain; Department of Molecular Biology and Biochemistry, University of Málaga, Málaga, Spain; Department of Neurology. Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya, Málaga, Spain; Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain; Multiple Sclerosis Unit, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Málaga, Spain; Red Española de Esclerosis Múltiple (REEM RD 07/0060), Málaga, Spain","Conceived and designed the experiments: CLG LL. Performed the experiments: CLG APA TOZ MJPM BOM JOP. Analyzed the data: CLG APA TOZ MJPM BOM FSJ. Contributed reagents/materials/analysis tools: CA CGC JV RAL EU OF. Wrote the paper: CLG APA OF LL.","Oscar Fernández, MD, PhD has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Almirall and Allergan. This study was partly funded by Biogen Idec Iberia S.L. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Carlos López-Gómez","CLG",14,TRUE,2,6,6,4,TRUE,TRUE,TRUE,4,"2;3;10;13",TRUE
